Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma.
Redox BiolMay 30, 2026 (epub)
Bente Sandvei Skeie, Alexander Richard Craig-Craven, Eli Renate Grüner et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase I dose-escalation trial investigated the safety and efficacy of sulfasalazine combined with stereotactic radiosurgery (SRS) in patients with recurrent glioblastoma. Twelve patients were enrolled, and results indicated that the combination therapy was well tolerated, with a median local tumor control improvement of 5.3 months compared to SRS alone (p < 0.001).
Key findings
- Two grade 3 adverse events were reported, indicating manageable safety.
- Tumor glutathione levels decreased significantly by day 3 (p = 0.010).
- Participants showed longer local tumor control with a median difference of 5.3 months (p < 0.001).
- Best RANO responses were significantly better in participants compared to controls (p = 0.001).
Why it matters
The findings suggest that combining sulfasalazine with SRS may enhance local tumor control in recurrent glioblastoma, potentially offering a new therapeutic strategy. Understanding the safety and efficacy of this combination could inform future treatment protocols.